Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment

NCT00932867 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3114

Last updated 2010-04-20

No results posted yet for this study

Summary

Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment

Conditions

Interventions

DRUG

Kinzal/Pritor (Telmisartan, BAY68-9291)

Patients under daily life treatment receiving Pritor according to local drug information.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-06-30
Completion
2009-08-31

Countries

  • Romania
  • Slovakia

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00932867 on ClinicalTrials.gov